DSpace university logo mark
Advanced Search
Japanese | English 

NAOSITE : Nagasaki University's Academic Output SITE > School of Medicine > Articles in academic journal >

Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa


File Description SizeFormat
IJH95_209.pdf404.02 kBAdobe PDFView/Open

Title: Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa
Authors: Itonaga, Hidehiro / Tsushima, Hideki / Hata, Tomoko / Matsuo, Emi / Imanishi, Daisuke / Imaizumi, Yoshitaka / Kawaguchi, Yasuhisa / Fukushima, Takuya / Doi, Yuko / Mori, Sayaka / Kamihira, Shimeru / Tomonaga, Masao / Miyazaki, Yasushi
Issue Date: Feb-2012
Citation: International Journal of Hematology, 95(2), pp.209-213; 2012
Abstract: The T315I BCR-ABL mutation in chronic myelogenous leukemia (CML) patients is responsible for up to 20% of all clinically observed resistance. This mutation confers resistance not only to imatinib, but also to second-generation BCR-ABL tyrosine kinases, such as nilotinib and dasatinib. A number of strategies have been implemented to overcome this resistance, but allogeneic stem cell transplantation remains the only established therapeutic option for a cure. A 61-year-old male was diagnosed with Philadelphia chromosome-positive chronic-phase CML in 2002. He was initially treated with imatinib and complete cytogenetic response (CCyR) was achieved 12 months later. However, after 18 months, a loss of CCyR was observed and a molecular study at 24 months revealed a T315I mutation of the BCR-ABL gene. At 30 months, imatinib/interferon-alfa (IFNα) combination therapy was initiated in an effort to overcome the resistance. Thirty months later, he re-achieved CCyR, and the T315I BCR-ABL mutation disappeared at 51 months. To our knowledge, this is the first case report showing the effectiveness of imatinib/IFNα combination therapy for CML patients bearing the T315I BCR-ABL mutation.
Keywords: Chronic myelogenous leukemia / Imatinib / Interferon / T315I
URI: http://hdl.handle.net/10069/27907
ISSN: 09255710
DOI: 10.1007/s12185-012-1005-1
Rights: © The Japanese Society of Hematology 2012 / The original publication is available at www.springerlink.com
Type: Journal Article
Text Version: author
Appears in Collections:Articles in academic journal

Citable URI : http://hdl.handle.net/10069/27907

All items in NAOSITE are protected by copyright, with all rights reserved.

 

Valid XHTML 1.0! Copyright © 2006-2015 Nagasaki University Library - Feedback Powerd by DSpace